Skip to main content

Advertisement

Table 1 Patient characteristics

From: A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer

Characteristic Training set (N = 100) Independent testing set (N = 75) In total (N = 175)
Age, y median (range) 63 (29–83) 63 (29–83) 63 (29–83)
 ≥ 63 51 (51%) 40 (53%) 91 (52%)
 < 63 49 (49%) 35 (47%) 84 (48%)
Sex    
 Male 74 (74%) 57 (76%) 131 (75%)
 Female 26 (26%) 18 (24%) 44 (25%)
Tumor Site    
 Distal stomach 34 (34%) 28 (37%) 62 (35%)
 Proximal stomach 41 (41%) 29 (39%) 70 (40%)
 Whole stomach 25 (25%) 18 (24%) 43 (25%)
Stage    
 I 13 (13%) 7 (9%) 20 (11%)
 II 20 (20%) 21 (28%) 41 (23%)
 III 65 (65%) 45 (60%) 110 (63%)
 IV 2 (2%) 2 (3%) 4 (3%)
Histological grade    
 2 20 (20%) 16 (21%) 36 (21%)
 3 47 (47%) 34 (46%) 81 (46%)
 Mixed 1–2 3 (3%) 3 (4%) 6 (3%)
 Mixed 2–3 30 (30%) 22 (29%) 52 (30%)
Lymph node metastasis    
 No 21 (21%) 19 (25%) 40 (23%)
 Yes 79 (79%) 56 (75%) 135 (77%)